NCT07224347 · ACTIVE NOT RECRUITING
Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)
ASPREE-XT is following older adults who were previously in the ASPREE aspirin trial to see what happens after they stopped taking aspirin. Researchers are watching for delayed effects on cancer, heart disease, stroke, dementia, and other outcomes. This is an observational follow-up, not a treatment study — no one is being given a drug. It is unphased, meaning it is ongoing data collection rather than a formal efficacy or safety test.
You may qualify if
- Men and women
- African American and Hispanic persons age 65 or older
- Any person from another ethnic minority group and Caucasian persons age 70 or older
- Willing and able to provide informed consent, and willing to accept the study requirements
You're excluded if
- A history of a diagnosed cardiovascular event
- A serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease
- A current or recurrent condition with a high risk of major bleeding, ex: cerebral aneurysm
- Anemia
- Absolute contraindication or allergy to aspirin
- Current participation in a clinical trial
- Current continuous use of aspirin or other anti-platelet drug or anticoagulant for secondary prevention. People with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low dose aspirin or placebo.
- A systolic blood pressure ≥180 mmHg and / or a diastolic blood pressure ≥105 mmHg
- A history of dementia
- Severe difficulty or an inability to perform any one of the 6 Katz ADLs
- Non-compliance to taking pill
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-11-04